[go: up one dir, main page]

WO1998022141A3 - Enhanced effects for hapten conjugated therapeutics - Google Patents

Enhanced effects for hapten conjugated therapeutics Download PDF

Info

Publication number
WO1998022141A3
WO1998022141A3 PCT/US1997/018475 US9718475W WO9822141A3 WO 1998022141 A3 WO1998022141 A3 WO 1998022141A3 US 9718475 W US9718475 W US 9718475W WO 9822141 A3 WO9822141 A3 WO 9822141A3
Authority
WO
WIPO (PCT)
Prior art keywords
enhanced effects
hapten conjugated
conjugate
half life
vivo half
Prior art date
Application number
PCT/US1997/018475
Other languages
French (fr)
Other versions
WO1998022141A2 (en
Inventor
Roland Buelow
Alexander R Lussow
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Priority to AU72983/98A priority Critical patent/AU7298398A/en
Priority to EP97949336A priority patent/EP1027073A2/en
Publication of WO1998022141A2 publication Critical patent/WO1998022141A2/en
Publication of WO1998022141A3 publication Critical patent/WO1998022141A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Novel methods for enhancing the effective in vivo half life of therapeutic compounds in mammals are provided. Specifically, therapeutic compounds are conjugated to a haptenic moiety. Upon administration to the mammalian subject, the therapeutic compound/hapten conjugates are bound by circulating antibodies directed specifically against the haptenic moiety of the conjugate, thereby resulting in a stabilization of the conjugate in the vascular system and an effective increase in the in vivo half life of the therapeutic compound.
PCT/US1997/018475 1996-11-19 1997-11-06 Enhanced effects for hapten conjugated therapeutics WO1998022141A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU72983/98A AU7298398A (en) 1996-11-19 1997-11-06 Enhanced effects for hapten conjugated therapeutics
EP97949336A EP1027073A2 (en) 1996-11-19 1997-11-06 Enhanced effects for hapten conjugated therapeutics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75267196A 1996-11-19 1996-11-19
US08/752,671 1996-11-19

Publications (2)

Publication Number Publication Date
WO1998022141A2 WO1998022141A2 (en) 1998-05-28
WO1998022141A3 true WO1998022141A3 (en) 1999-01-07

Family

ID=25027301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018475 WO1998022141A2 (en) 1996-11-19 1997-11-06 Enhanced effects for hapten conjugated therapeutics

Country Status (3)

Country Link
EP (1) EP1027073A2 (en)
AU (1) AU7298398A (en)
WO (1) WO1998022141A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
MXPA01003770A (en) 1998-10-13 2002-05-06 Univ Georgia Res Found Stabilized bioactive peptides and methods of identification, synthesis and use.
WO2001032207A1 (en) * 1998-10-30 2001-05-10 United States Army Medical Research And Materiel Command Methods for conferring active/passive immunotherapy
EP1757701A1 (en) * 1999-12-24 2007-02-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
KR20040058229A (en) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 Antibody targeting compounds
RU2464276C2 (en) 2005-05-18 2012-10-20 Аблинкс Н.В. Improved nanobodies against tumour necrosis factor-alpha
EP2115004A2 (en) 2006-12-19 2009-11-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
AU2007336243B2 (en) 2006-12-19 2012-07-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
AU2009273251B2 (en) 2008-07-22 2014-12-18 Ablynx Nv Amino acid sequences directed against multitarget scavenger receptors and polypeptides
SG174862A1 (en) 2009-04-10 2011-11-28 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorder
CN105061592A (en) 2009-06-05 2015-11-18 埃博灵克斯股份有限公司 Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
CA2791951C (en) 2010-05-20 2019-05-14 Ablynx Nv Biological materials related to her3
KR101650995B1 (en) 2010-11-08 2016-08-25 노파르티스 아게 Cxcr2 binding polypeptides
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх POLYPEPTIDE AGAINST IL-17A, IL-17F AND / OR IL17-A / F
JP2014525736A (en) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． Immunoglobulin single variable domain for IgE
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
KR20240076829A (en) 2016-11-16 2024-05-30 아블린쓰 엔.브이. T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
TWI811220B (en) 2017-06-02 2023-08-11 比利時商艾伯林克斯公司 Aggrecan binding immunoglobulins
JP7369127B2 (en) 2017-12-28 2023-10-25 ナンジン レジェンド バイオテック カンパニー，リミテッド Single domain antibodies against TIGIT and variants thereof
SG11202004233UA (en) 2018-01-15 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against pd-1
JP7346790B2 (en) 2018-03-30 2023-09-20 ナンジン レジェンド バイオテック カンパニー，リミテッド Single domain antibodies against LAG-3 and their uses
EP4294834A2 (en) 2021-02-19 2023-12-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Single domain antibodies that neutralize sars-cov-2
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017699A1 (en) * 1992-03-02 1993-09-16 The Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by hla peptides
DE4238416A1 (en) * 1992-11-13 1994-05-19 Max Planck Gesellschaft Determination of peptide motifs on MHC molecules
WO1995034321A1 (en) * 1994-06-16 1995-12-21 The Board Of Trustees Of The Leland Stanford Junior University Immune modulation with class ii alpha-chain fragments
WO1996035443A1 (en) * 1995-05-12 1996-11-14 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease
WO1997024140A1 (en) * 1996-01-02 1997-07-10 The Board Of Trustees Of Leland Stanford Junior University Interaction of hla proteins with members of the hsp70 family of proteins
WO1997037690A2 (en) * 1996-04-10 1997-10-16 Sangstat Medical Corporation Cytomodulating conjugates of members of specific binding pairs

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017699A1 (en) * 1992-03-02 1993-09-16 The Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by hla peptides
DE4238416A1 (en) * 1992-11-13 1994-05-19 Max Planck Gesellschaft Determination of peptide motifs on MHC molecules
WO1995034321A1 (en) * 1994-06-16 1995-12-21 The Board Of Trustees Of The Leland Stanford Junior University Immune modulation with class ii alpha-chain fragments
WO1996035443A1 (en) * 1995-05-12 1996-11-14 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease
WO1997024140A1 (en) * 1996-01-02 1997-07-10 The Board Of Trustees Of Leland Stanford Junior University Interaction of hla proteins with members of the hsp70 family of proteins
WO1997037690A2 (en) * 1996-04-10 1997-10-16 Sangstat Medical Corporation Cytomodulating conjugates of members of specific binding pairs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUELOW R ET AL: "PROLONGATION OF SKIN ALLOGRAFT SURVIVAL IN MICE FOLLOWING ADMINISTRATION OF ALLOTRAP", TRANSPLANTATION, vol. 59, no. 4, 27 February 1995 (1995-02-27), pages 455 - 460, XP000652975 *
LUSSOW A R ET AL: "REDIRECTING CIRCULATING ANTIBODIES VIA LIGAND-HAPTEN CONJUGATES ELIMINATES TARGET CELLS IN VIVO", JOURNAL OF IMMUNOTHERAPY: WITH EMPHASIS ON TUMOR IMMUNOLOGY, vol. 19, no. 4, July 1996 (1996-07-01), pages 257 - 265, XP002050531 *

Also Published As

Publication number Publication date
EP1027073A2 (en) 2000-08-16
AU7298398A (en) 1998-06-10
WO1998022141A2 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
WO1998022141A3 (en) Enhanced effects for hapten conjugated therapeutics
WO1997029779A3 (en) EGF-Genistein conjugates for the treatment of cancer
ZA964614B (en) Methods for the preparation of substantially monomeric callcheamicin derivative carrier conjugates.
AU2582488A (en) Drug-monoclonal antibody conjugates
ID19188A (en) METHODS FOR PRODUCING CONJUGATION LINOLEATE ACID
EP0911036A3 (en) Dual carrier immunogenic construct
EP1374908A3 (en) Polymer-drug conjugates comprising hydrazide linkers
FI973002A0 (en) Therapeutic compound - fatty acid conjugate
FR2696176B1 (en) Piperidine derivatives, their preparation and their therapeutic application.
IL146015A0 (en) Methods for producing 5'-nucleic acid-protein conjugates
CA2101648A1 (en) Polysaccharide-protein conjugates
AU3076601A (en) Chemically-programmable immunity
TR199902775T2 (en) (S) -Camptothecin glycoconjugeleri.
AU2162202A (en) Antitumor therapy comprising distamycin derivatives
HUP0001069A3 (en) Method for producing an igm preparation for intravenous administration
CA2098593A1 (en) Treatment method for cancer
FR2696177B1 (en) Piperidine derivatives, their preparation and their therapeutic application.
AU7915391A (en) In vivo targeting with bifunctional antibodies
AU3991899A (en) Verotoxin b subunit for immunization
NZ501832A (en) Angiotensin-peptide carrier conjugates for treating diseases associated with the renin-angiotensin system
CA2190867A1 (en) Methods for reduced renal uptake of antibody fragments
WO2001040239A3 (en) Transition metal-cyclopentadienyl-tropane conjugates
FR2719844B1 (en) 5,6-dihydro-4h-thieno [3,4-c] pyrrole derivatives, their preparation and their therapeutic use.
CA2109572A1 (en) Method for reducing side-effects of a drug
FR2697520B1 (en) Benz [e] indende derivatives.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1997949336

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWP Wipo information: published in national office

Ref document number: 1997949336

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997949336

Country of ref document: EP